BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 21070597)

  • 1. AMD3100 is a potent antagonist at CXCR4(R334X) , a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome.
    McDermott DH; Lopez J; Deng F; Liu Q; Ojode T; Chen H; Ulrick J; Kwatemaa N; Kelly C; Anaya-O'Brien S; Garofalo M; Marquesen M; Hilligoss D; DeCastro R; Malech HL; Murphy PM
    J Cell Mol Med; 2011 Oct; 15(10):2071-81. PubMed ID: 21070597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.
    McDermott DH; Liu Q; Ulrick J; Kwatemaa N; Anaya-O'Brien S; Penzak SR; Filho JO; Priel DA; Kelly C; Garofalo M; Littel P; Marquesen MM; Hilligoss D; Decastro R; Fleisher TA; Kuhns DB; Malech HL; Murphy PM
    Blood; 2011 Nov; 118(18):4957-62. PubMed ID: 21890643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4.
    Liu Q; Chen H; Ojode T; Gao X; Anaya-O'Brien S; Turner NA; Ulrick J; DeCastro R; Kelly C; Cardones AR; Gold SH; Hwang EI; Wechsler DS; Malech HL; Murphy PM; McDermott DH
    Blood; 2012 Jul; 120(1):181-9. PubMed ID: 22596258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a new WHIM syndrome mutant reveals mechanistic differences in regulation of the chemokine receptor CXCR4.
    Luo J; De Pascali F; Richmond GW; Khojah AM; Benovic JL
    J Biol Chem; 2022 Feb; 298(2):101551. PubMed ID: 34973340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WHIM Syndrome Caused by Waldenström's Macroglobulinemia-Associated Mutation CXCR4 (L329fs).
    Liu Q; Pan C; Lopez L; Gao J; Velez D; Anaya-O'Brien S; Ulrick J; Littel P; Corns JS; Ellenburg DT; Malech HL; Murphy PM; McDermott DH
    J Clin Immunol; 2016 May; 36(4):397-405. PubMed ID: 27059040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCR4-Specific Nanobodies as Potential Therapeutics for WHIM syndrome.
    de Wit RH; Heukers R; Brink HJ; Arsova A; Maussang D; Cutolo P; Strubbe B; Vischer HF; Bachelerie F; Smit MJ
    J Pharmacol Exp Ther; 2017 Oct; 363(1):35-44. PubMed ID: 28768817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Filamin A interaction with the CXCR4 third intracellular loop regulates endocytosis and signaling of WT and WHIM-like receptors.
    Gómez-Moutón C; Fischer T; Peregil RM; Jiménez-Baranda S; Stossel TP; Nakamura F; Mañes S
    Blood; 2015 Feb; 125(7):1116-25. PubMed ID: 25355818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced function with decreased internalization of carboxy-terminus truncated CXCR4 responsible for WHIM syndrome.
    Kawai T; Choi U; Whiting-Theobald NL; Linton GF; Brenner S; Sechler JM; Murphy PM; Malech HL
    Exp Hematol; 2005 Apr; 33(4):460-8. PubMed ID: 15781337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetics on a WHIM.
    Al Ustwani O; Kurzrock R; Wetzler M
    Br J Haematol; 2014 Jan; 164(1):15-23. PubMed ID: 24111611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and genetic features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome.
    Dotta L; Tassone L; Badolato R
    Curr Mol Med; 2011 Jun; 11(4):317-25. PubMed ID: 21506920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebellar involvement in warts Hypogammaglobulinemia immunodeficiency myelokathexis patients: neuroimaging and clinical findings.
    Galli J; Pinelli L; Micheletti S; Palumbo G; Notarangelo LD; Lougaris V; Dotta L; Fazzi E; Badolato R
    Orphanet J Rare Dis; 2019 Feb; 14(1):61. PubMed ID: 30819232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.
    McDermott DH; Liu Q; Velez D; Lopez L; Anaya-O'Brien S; Ulrick J; Kwatemaa N; Starling J; Fleisher TA; Priel DA; Merideth MA; Giuntoli RL; Evbuomwan MO; Littel P; Marquesen MM; Hilligoss D; DeCastro R; Grimes GJ; Hwang ST; Pittaluga S; Calvo KR; Stratton P; Cowen EW; Kuhns DB; Malech HL; Murphy PM
    Blood; 2014 Apr; 123(15):2308-16. PubMed ID: 24523241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CXCR4 mutations in WHIM syndrome impair the stability of the T-cell immunologic synapse.
    Kallikourdis M; Trovato AE; Anselmi F; Sarukhan A; Roselli G; Tassone L; Badolato R; Viola A
    Blood; 2013 Aug; 122(5):666-73. PubMed ID: 23794067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WHIM syndrome myelokathexis reproduced in the NOD/SCID mouse xenotransplant model engrafted with healthy human stem cells transduced with C-terminus-truncated CXCR4.
    Kawai T; Choi U; Cardwell L; DeRavin SS; Naumann N; Whiting-Theobald NL; Linton GF; Moon J; Murphy PM; Malech HL
    Blood; 2007 Jan; 109(1):78-84. PubMed ID: 16946301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromothriptic cure of WHIM syndrome.
    McDermott DH; Gao JL; Liu Q; Siwicki M; Martens C; Jacobs P; Velez D; Yim E; Bryke CR; Hsu N; Dai Z; Marquesen MM; Stregevsky E; Kwatemaa N; Theobald N; Long Priel DA; Pittaluga S; Raffeld MA; Calvo KR; Maric I; Desmond R; Holmes KL; Kuhns DB; Balabanian K; Bachelerie F; Porcella SF; Malech HL; Murphy PM
    Cell; 2015 Feb; 160(4):686-699. PubMed ID: 25662009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of Sustained Neutrophilia in Patient WHIM-09, Cured of WHIM Syndrome by Chromothripsis.
    Liu Q; Li Z; Y Yang A; Gao JL; S Velez D; J Cho E; McDermott DH; Murphy PM
    J Clin Immunol; 2018 Jan; 38(1):77-87. PubMed ID: 29177911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotype-phenotype correlations in WHIM syndrome: a systematic characterization of CXCR4
    Zmajkovicova K; Pawar S; Maier-Munsa S; Maierhofer B; Wiest I; Skerlj R; Taveras AG; Badarau A
    Genes Immun; 2022 Sep; 23(6):196-204. PubMed ID: 36089616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe CD8+ T Lymphopenia in WHIM Syndrome Caused by Selective Sequestration in Primary Immune Organs.
    Majumdar S; Pontejo SM; Jaiswal H; Gao JL; Salancy A; Stassenko E; Yamane H; McDermott DH; Balabanian K; Bachelerie F; Murphy PM
    J Immunol; 2023 Jun; 210(12):1913-1924. PubMed ID: 37133343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome.
    McDermott DH; Velez D; Cho E; Cowen EW; DiGiovanna JJ; Pastrana DV; Buck CB; Calvo KR; Gardner PJ; Rosenzweig SD; Stratton P; Merideth MA; Kim HJ; Brewer C; Katz JD; Kuhns DB; Malech HL; Follmann D; Fay MP; Murphy PM
    J Clin Invest; 2023 Oct; 133(19):. PubMed ID: 37561579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The negative charge of the 343 site is essential for maintaining physiological functions of CXCR4.
    Wang L; Xiong Q; Li P; Chen G; Tariq N; Wu C
    BMC Mol Cell Biol; 2021 Jan; 22(1):8. PubMed ID: 33485325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.